<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03774459</url>
  </required_header>
  <id_info>
    <org_study_id>ANAVEX2-73-PDD-001</org_study_id>
    <nct_id>NCT03774459</nct_id>
  </id_info>
  <brief_title>ANAVEX2-73 Study in Parkinson's Disease Dementia</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anavex Life Sciences Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anavex Germany GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anavex Life Sciences Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety,
      Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with
      Parkinson's Disease with Dementia (PDD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group,
      three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening
      / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration
      Period), and a 2-week Safety Follow-Up Period
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention</measure>
    <time_frame>14 weeks</time_frame>
    <description>Change from Baseline to End of Treatment in Continuity of Attention as measured by Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>14 weeks</time_frame>
    <description>Assess the safety and tolerability of ANAVEX2-73 compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MDS-UPDRS Part III Total Score (Motor Scores)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Change from baseline to End of Treatment as measured by MDS-UPDRS Part III Total Score (Motor Scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDS-CL-25</measure>
    <time_frame>14 weeks</time_frame>
    <description>Incidence of sleep disorders symptoms (SDS-CL-25)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Parkinsons Disease With Dementia</condition>
  <arm_group>
    <arm_group_label>High dose ANAVEX2-73</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose ANAVEX2-73</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose ANAVEX2-73</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid dose ANAVEX2-73</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose ANAVEX2-73</intervention_name>
    <description>Active oral capsule</description>
    <arm_group_label>High dose ANAVEX2-73</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mid dose ANAVEX2-73</intervention_name>
    <description>Active oral capsule</description>
    <arm_group_label>Mid dose ANAVEX2-73</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo oral capsule</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic Parkinson's disease (PD) consistent with the UK Parkinson's
             Disease Society Brain Bank diagnostic criteria.

          -  Diagnosis of probable PD dementia (PDD) according to the Movement Disorder Society
             Task Force clinical diagnostic criteria.

          -  Montreal Cognitive Assessment (MoCA) score of 13 to 23, inclusive, at Screening.

          -  Male or female and aged ≥ 50 years.

          -  Caregivers and subjects (or legal representative) must understand and have signed
             approved informed consent.

          -  Caregivers and subjects (or legal representative) must be able to understand study
             requirements and be willing to follow instructions.

          -  Stable regimen of anti-Parkinson's disease medications (including levodopa, dopamine
             agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable
             for at least 4 weeks prior to Baseline.

          -  Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine
             (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable
             for a minimum of 8 weeks prior to randomization.

          -  Subjects with history of depression on antidepressant medications will be allowed if
             depression is controlled and they have been on a stable daily dose of the
             antidepressant for ≥8 weeks before Baseline.

          -  Contraception:

               -  Women of childbearing potential must use an acceptable method of contraception
                  starting 4 weeks prior to study drug administration and for a minimum of 4 weeks
                  after study completion. Otherwise, women must be postmenopausal (at least one
                  year absence of vaginal bleeding or spotting) as confirmed by FSH greater than or
                  equal to 40 mIU/mL or 40 IU/L or be surgically sterile.

               -  Men with a potentially fertile partner must have had a vasectomy or be willing to
                  use an acceptable method of contraception for the duration of the study and for 3
                  months after study drug discontinuation.

        Exclusion Criteria:

          -  History of any significant neurologic or psychiatric disorder other than PD that can
             contribute to cognitive impairment.

          -  Any other condition or clinically significant abnormal findings like severe
             co-morbidities e.g. history of stroke, poor kidney or liver function on the physical
             or neurological examination, medical and psychiatric history, at screening or at
             baseline that, in the opinion of the Investigator, would make the subject unsuitable
             for the study.

          -  Potential symptomatic causes of cognitive impairment including but not limited to

               1. abnormal thyroid function test at screening (TSH)

               2. abnormal B12 level at screening

               3. MRI findings (by history) pointing to a potential symptomatic cause of cognitive
                  dysfunction, including significant vascular changes, or communicating
                  hydrocephalus.

          -  Treatment with memantine or amantadine. If appropriate the drugs can be discontinued
             for a minimum of 4 weeks prior to randomization.

          -  Use of over the counter (OTC) or prescription medication for sleep on 2 or more
             occasions per week (less than that is allowed).

          -  History of depression as measured by Beck Depression Inventory score &gt;17 at screening.

          -  Treatment with any other investigational drug or device within 4 weeks prior to
             screening.

          -  Smoking &gt; 1 pack of cigarettes per day (as assessed for the 4 weeks prior to
             screening).

          -  Women who are pregnant or lactating.

          -  Known allergy or sensitivity to ANAVEX2-73 or any of its components.

          -  Suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) of type 4 or
             type 5, or any suicidal behavior, in the past 6 months. Type 4 indicates active
             suicidal ideation with some intent to act, without a specific plan. Type 5 indicates
             active suicidal ideation with a specific plan and intent.

          -  Use of centrally acting anticholinergic drugs during the 4 weeks before randomization.

          -  Medications used for overactive bladder will be allowed provided that the regimen has
             been stable 4 weeks prior to randomization.

          -  Treatment with any dopamine receptor blocking medications with the exception of low
             dose quetiapine (≤50 mg/day). Pimavanserin (≤34 mg/day) will be allowed.

          -  History of neurosurgical intervention (e.g., deep brain stimulation) for PD.

          -  Unpredictable motor fluctuations that would interfere with administering cognitive
             assessments in the ON state.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KaRa MINDS</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammond Health</name>
      <address>
        <city>Malvern</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cruces Bilbao</name>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua Terrasa</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Henares</name>
      <address>
        <city>Coslada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Caterina</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra (CUN) - Sede Madrid- Servicio de Neurología -</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leónor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital HM Puerta del Sur</name>
      <address>
        <city>Móstoles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias (HUCA)</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra (CUN)</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 8, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2018</study_first_posted>
  <last_update_submitted>March 8, 2020</last_update_submitted>
  <last_update_submitted_qc>March 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

